The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates:
wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
本发明涉及式(I)的新型大环化合物及其药学上可接受的盐、
水合物或溶液:
其中 R1、R2、R3、R4、R5、R6、n1、m、p Z1、Z2 和 Z3 如说明书所述。本发明还涉及式(I)化合物,该化合物是动情素受体的拮抗剂,可用于治疗与该受体相关的疾病以及运动功能障碍。